This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy
Molecular Cancer Open Access 11 November 2023
-
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Experimental Hematology & Oncology Open Access 02 March 2022
-
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
Current Oncology Reports Open Access 13 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dombret H, Gardin C . An update of current treatments for adult acute myeloid leukemia. Blood 2016; 127: 53–61.
Barrett AJ, Battiwalla M . Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 2010; 3: 429–441.
Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol 2013; 31: 3259–3271.
Sauer T, Silling G, Groth C, Rosenow F, Krug U, Görlich D et al. Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. Bone Marrow Transplant 2015; 50: 485–492.
Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.
Armand P . Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393–3400.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.
Topalian SL, Drake CG, Pardoll DM . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27: 450–461.
Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 443–445.
Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 850–852.
Chan TS, Khong PL, Kwong YL . Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol 2016; 95: 1913–1915.
Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant 2016; 51: 1268–1270.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139–148.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Albring, J., Inselmann, S., Sauer, T. et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone Marrow Transplant 52, 317–320 (2017). https://doi.org/10.1038/bmt.2016.274
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.274
This article is cited by
-
Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy
Molecular Cancer (2023)
-
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Experimental Hematology & Oncology (2022)
-
Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
Current Oncology Reports (2021)
-
Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab
Annals of Hematology (2021)
-
Lenalidomide as a Potent Inducer of Graft Versus Leukemia Effect in Patients with Hematologic Malignancies at High Risk of Relapse Post Allogeneic Stem Cell Transplant
Indian Journal of Hematology and Blood Transfusion (2021)